Avidea Technologies Revenue and Competitors
Estimated Revenue & Valuation
- Avidea Technologies's estimated annual revenue is currently $2.5M per year.
- Avidea Technologies's estimated revenue per employee is $155,000
Employee Data
- Avidea Technologies has 16 Employees.
- Avidea Technologies grew their employee count by -38% last year.
Avidea Technologies's People
Name | Title | Email/Phone |
---|---|---|
1 | Head Operations | Reveal Email/Phone |
Avidea Technologies Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $0.3M | 2 | -60% | N/A | N/A |
#2 | $2.9M | 38 | -31% | $17.5M | N/A |
#3 | $2.9M | 38 | -33% | $10.5M | N/A |
#4 | $19.8M | 128 | 0% | $69.4M | N/A |
#5 | $9.6M | 62 | -15% | N/A | N/A |
#6 | $1.4M | 9 | 0% | N/A | N/A |
#7 | $2.5M | 16 | 0% | N/A | N/A |
#8 | $7.4M | 48 | 0% | N/A | N/A |
#9 | $0.2M | 1 | -83% | N/A | N/A |
#10 | $1.7M | 11 | 22% | N/A | N/A |
What Is Avidea Technologies?
Our mission: To develop safer and more effective immunotherapies through innovations in drug delivery. Avidea Technologies is a leader in the development of polymer-based drug delivery systems with immunotherapeutic applications. Our technology and team are building on more than two decades of pioneering work by our world-class scientific founders and advisors from the National Institutes of Health, the University of Oxford and the Institute for Macromolecular Chemistry. Our founders, advisors and collaborators are experts in the fields of immunology, oncology, vaccines and drug-delivery. We apply the interdisciplinary expertise of our team to overcome key challenges in drug delivery and advance promising immunotherapies to patients in need.
keywords:N/AN/A
Total Funding
16
Number of Employees
$2.5M
Revenue (est)
-38%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $2.5M | 16 | 0% | N/A |
#2 | $1.2M | 16 | -6% | $34.7M |
#3 | $2.4M | 16 | -11% | N/A |
#4 | $4M | 16 | 7% | N/A |
#5 | $4M | 16 | 7% | N/A |